Role of Ruxolitinib in GVHD Treatment
Drs Michael Bishop and John DiPersio comment on clinical implications for the use of ruxolitinib in chronic GVHD and share insights on future directions for GVHD.
Practical Considerations for the Treatment of GVHD
Expert hematologist/oncologists consider combination therapy with ROCK and JAK inhibitors for the treatment of chronic GVHD as well as the use of ibrutinib for disease management.
JAK Inhibitors: Managing Cytopenias in Chronic GVHD
Michael Bishop, MD, and John DiPersio, MD, PhD, discuss pulmonary complications associated with chronic GVHD and the management of cytopenias in patients treated with JAK inhibitors.
Challenges in Managing Chronic GvHD
Drs Michael Bishop and John DiPersio comment on common challenges in measuring response in chronic GvHD and review clinical implication from the REACH3 trial.
Management of Chronic GvHD
Experts in hematology/oncology review factors to consider when approaching the management of chronic graft-versus-host disease.
Third-Line Treatment Approaches for Acute GVHD
John DiPersio, MD, PhD, and Michael Bishop, MD, discuss third-line treatment options for patients with acute and steroid-refractory GVHD.
Approaching Initial Treatment of Chronic GVHD
John DiPersio, MD, PhD, shares his thoughts on approaching initial therapy for chronic GVHD and early intervention with JAK inhibitors.
Frontline Management of GVHD
Michael Bishop, MD, leads the discussion on approaching the first-line management of acute GVHD and the importance of early intervention for patients at risk for the disease.
Risk Factors for GVHD
Expert hematologist-oncologists provide insight on major risk factors for GVHD and associated challenges for treatment.
Role of Early Intervention in GVHD Treatment
Dr John DiPersio discusses an early intervention approach to the management of chronic and acute GVHD.
Overview of Graft vs Host Disease (GVHD)
John DiPersio, MD, PhD, and Michael Bishop, MD, define acute and chronic graft-vs-host disease (GVHD).
CAR T Cells Have Reshaped the Hematologic Cancer Landscape
Michael Bishop, MD, discusses the different settings where chimeric antigen receptor T-cell therapy are used.
Investigating CAR T-Cell Therapy for Use in Different Disease Types
Michael Bishop, MD, discusses the investigations of and responses to chimeric antigen receptor T-cell therapy in different disease types.
Managing Acute GVHD in Community Settings
Newer therapies being explored to address treatment gaps in acute graft-versus-host disease (GVHD), and advice to community oncologists/hematologists who manage cases of GVHD and/or care for patients who receive allotransplants.
Using Ruxolitinib to Treat Steroid-Refractory Acute GVHD
The rationale for treating steroid-refractory acute graft-versus-host disease with ruxolitinib, a JAK inhibitor, and recommendations for monitoring and managing treatment-related adverse events.
The REACH2 Study in Steroid-Refractory Acute GVHD
Dr Michael Bishop, of the David and Etta Jonas Center for Cellular Therapy, University of Chicago, describes the rationale for the design of the phase 3 REACH2 trial in steroid-refractory acute graft-versus-host disease and provides perspective on important takeaways from data presented.
Acute GVHD: Assessing Response to Steroid Therapy
Considerations for assessing response to steroid therapy as initial therapy for acute graft-versus-host disease and factors that impact next-line therapy, when necessary.
Steroid-Refractory Acute Graft-Versus-Host Disease Defined
Michael Bishop, MD, shares recommendations that can help hematologists/oncologists appropriately identify patients with steroid-refractory acute graft-versus-host disease and describes how his treatment approaches differ based on grade.
Acute Graft-Versus-Host Disease: Diagnostic Criteria & Prevention
Criteria used by hematologists/oncologists to diagnose acute graft-versus-host disease (GVHD), and common therapies used for GVHD prevention in patients who receive hematopoietic stem cell transplantation.
Case Assessment: 53-Year-Old With Steroid-Refractory Acute GVHD
Michael Bishop, MD, discusses his concerns for a 53-year-old man diagnosed with acute graft-versus-host disease later deemed as steroid refractory, based on the typical prognosis for patients in similar scenarios.
A 53-Year-Old Man With Steroid-Refractory Acute Graft-Versus-Host Disease
Recommendations for using ruxolitinib to treat a 53-year-old patient with acute graft-versus-host disease whose disease progresses following previous treatment with steroid therapy.
2 Clarke Drive Cranbury, NJ 08512